A Double Blind (3rd Party Open), Randomized, Placebo Controlled, Dose Escalation Study To Investigate The Safety, Toleration, And Pharmacokinetics Of Multiple Oral Doses Of PF-03654764 In Healthy Subjects.
Phase of Trial: Phase I
Latest Information Update: 17 Dec 2009
At a glance
- Drugs PF 3654764 (Primary)
- Indications Cognition disorders
- Focus Adverse reactions
- Sponsors Pfizer
- 17 Dec 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 28 Oct 2009 Additional locations (Singapore) added as reported by ClinicalTrials.gov.
- 28 Oct 2009 Status changed from not yet recruiting to recruiting.